Anti-Rheumatics Market by Product Type, Route Of Administration, Drug Class, Disease Type - Global Forecast 2025-2030- Product Image

Sale

Anti-Rheumatics Market by Product Type, Route Of Administration, Drug Class, Disease Type - Global Forecast 2025-2030

Report
199 Pages
October 2024
Region: Global
360iResearch™
ID: 6014950

UP TO €692EUR$697USD£576GBP OFF until Dec 31^st 2024

The Anti-Rheumatics Market grew from USD 60.67 billion in 2023 to USD 63.28 billion in 2024. It is expected to continue growing at a CAGR of 5.12%, reaching USD 86.09 billion by 2030.

The anti-rheumatics market encompasses the development and commercialization of medications aimed at treating rheumatic diseases, primarily focusing on conditions like rheumatoid arthritis, osteoarthritis, and psoriatic arthritis. The necessity of anti-rheumatics arises from the high prevalence of these chronic conditions, demanding effective treatments for pain relief, inflammation reduction, and improved mobility. Applications span across oral, injectable, and biologic therapeutics, with end-use sectors including hospitals, clinics, and home care settings. Key factors influencing market growth include the aging population, rising incidence of arthritis due to lifestyle changes, and advancements in biologics and biosimilars. Notably, the increasing adoption of disease-modifying antirheumatic drugs (DMARDs) is significant, as they provide long-term improvement in patients' conditions. Market opportunities exist in the expansion of personalized medicine and the development of more targeted therapeutic agents, which could improve treatment efficacy and reduce adverse effects. Additionally, the integration of digital health solutions, such as wearables and telemedicine, offers a promising avenue for patient monitoring and management, optimizing treatment regimens. However, market growth faces limitations such as high costs of biologic therapies and stringent regulatory frameworks hindering new drug approvals. Other challenges include addressing the side effects associated with long-term medication usage and ensuring equitable access to advanced treatments. To foster innovation, investments can be directed towards genomics and biomarker research to enable more precise targeting of therapies, offering new hope for patients with challenging-to-treat forms of arthritis. The market is characterized by a competitive landscape with significant R&D investments from pharmaceutical companies, necessitating strategic collaborations and partnerships to boost research capabilities and market reach. As the market evolves, stakeholders should focus on maintaining affordability and accessibility of cutting-edge treatments, which are crucial for sustaining growth and enhancing patient outcomes.

Understanding Market Dynamics in the Anti-Rheumatics Market

The Anti-Rheumatics Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Innovative drug delivery systems enhancing patient compliance and therapeutic outcomes in anti-rheumatics
- Government initiatives and favorable reimbursement policies driving market growth
- Expansion of clinical trials and R&D activities for novel anti-rheumatic treatments
- Increased patient access to healthcare services improving the adoption of anti-rheumatic medications
Market Restraints
- Limited availability of advanced biological therapies in underdeveloped regions affecting treatment access and equity
- Low patient adherence to prescribed treatment regimens leading to suboptimal therapeutic outcomes and increased disease burden
Market Opportunities
- Increasing prevalence of rheumatoid arthritis among geriatric population driving demand for anti-rheumatics
- Growing investment in research and development initiatives for novel anti-rheumatic drugs
- Rising awareness among patients and healthcare providers about early diagnosis and treatment of rheumatoid arthritis
Market Challenges
- The need for better diagnostic tools and biomarkers to improve early detection and treatment outcomes in rheumatoid arthritis
- The challenge of managing comorbidities and side effects associated with long-term use of anti-rheumatic medications

Exploring Porter’s Five Forces for the Anti-Rheumatics Market

Porter’s Five Forces framework further strengthens the insights of the Anti-Rheumatics Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Anti-Rheumatics Market

External macro-environmental factors deeply influence the performance of the Anti-Rheumatics Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Anti-Rheumatics Market

The Anti-Rheumatics Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Anti-Rheumatics Market

The Anti-Rheumatics Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Anti-Rheumatics Market

The Anti-Rheumatics Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Rheumatics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca plc, Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Galapagos NV, Gilead Sciences, Inc., GlaxoSmithKline plc, ILTOO Pharma, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., UCB S.A., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Anti-Rheumatics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product Type
- Biologics
  - IL-1 Inhibitors
  - IL-6 Inhibitors
  - JAK Inhibitors
  - TNF Inhibitors
- Non-Biologics
  - Corticosteroids
  - DMARDs
  - NSAIDs
Route Of Administration
- Injectable
- Oral
- Topical
Drug Class
- Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
  - Biologic DMARDs
    - Biosimilar DMARDs
  - Synthetic DMARDs
    - Conventional Synthetic DMARDs
    - Targeted Synthetic DMARDs
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Disease Type
- Ankylosing Spondylitis
- Osteoarthritis
- Psoriatic Arthritis
- Rheumatoid Arthritis

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Innovative drug delivery systems enhancing patient compliance and therapeutic outcomes in anti-rheumatics
5.1.1.2. Government initiatives and favorable reimbursement policies driving market growth
5.1.1.3. Expansion of clinical trials and R&D activities for novel anti-rheumatic treatments
5.1.1.4. Increased patient access to healthcare services improving the adoption of anti-rheumatic medications
5.1.2. Restraints
5.1.2.1. Limited availability of advanced biological therapies in underdeveloped regions affecting treatment access and equity
5.1.2.2. Low patient adherence to prescribed treatment regimens leading to suboptimal therapeutic outcomes and increased disease burden
5.1.3. Opportunities
5.1.3.1. Increasing prevalence of rheumatoid arthritis among geriatric population driving demand for anti-rheumatics
5.1.3.2. Growing investment in research and development initiatives for novel anti-rheumatic drugs
5.1.3.3. Rising awareness among patients and healthcare providers about early diagnosis and treatment of rheumatoid arthritis
5.1.4. Challenges
5.1.4.1. The need for better diagnostic tools and biomarkers to improve early detection and treatment outcomes in rheumatoid arthritis
5.1.4.2. The challenge of managing comorbidities and side effects associated with long-term use of anti-rheumatic medications
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Anti-Rheumatics Market, by Product Type

6.1. Introduction
6.2. Biologics
6.2.1. IL-1 Inhibitors
6.2.2. IL-6 Inhibitors
6.2.3. JAK Inhibitors
6.2.4. TNF Inhibitors
6.3. Non-Biologics
6.3.1. Corticosteroids
6.3.2. DMARDs
6.3.3. NSAIDs

7. Anti-Rheumatics Market, by Route Of Administration

7.1. Introduction
7.2. Injectable
7.3. Oral
7.4. Topical

8. Anti-Rheumatics Market, by Drug Class

8.1. Introduction
8.2. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
8.2.1. Biologic DMARDs
8.2.1.1. Biosimilar DMARDs
8.2.2. Synthetic DMARDs
8.2.2.1. Conventional Synthetic DMARDs
8.2.2.2. Targeted Synthetic DMARDs
8.3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

9. Anti-Rheumatics Market, by Disease Type

9.1. Introduction
9.2. Ankylosing Spondylitis
9.3. Osteoarthritis
9.4. Psoriatic Arthritis
9.5. Rheumatoid Arthritis

10. Americas Anti-Rheumatics Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Anti-Rheumatics Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Anti-Rheumatics Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation

List of Figures

FIGURE 1. ANTI-RHEUMATICS MARKET RESEARCH PROCESS
FIGURE 2. ANTI-RHEUMATICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. ANTI-RHEUMATICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. ANTI-RHEUMATICS MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. ANTI-RHEUMATICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANTI-RHEUMATICS MARKET DYNAMICS
TABLE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY IL-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY IL-6 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DMARDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOSIMILAR DMARDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CONVENTIONAL SYNTHETIC DMARDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TARGETED SYNTHETIC DMARDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 45. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 64. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 67. CANADA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 68. CANADA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 69. CANADA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 70. CANADA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 73. CANADA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 74. CANADA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 75. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 76. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 79. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 82. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 83. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 84. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 96. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 98. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 102. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 103. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 104. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 105. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 106. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 107. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 108. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 110. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 111. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 112. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 113. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 114. CHINA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 115. CHINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 116. CHINA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 117. CHINA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 120. CHINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 121. CHINA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 122. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 123. INDIA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 124. INDIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 125. INDIA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 126. INDIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 129. INDIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 130. INDIA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 131. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 132. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 133. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 134. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 135. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 138. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 139. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 140. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 141. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 142. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 143. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 144. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 146. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 147. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 148. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 149. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 150. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 151. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 152. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 153. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 155. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 156. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 157. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 158. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 159. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 160. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 161. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 162. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 165. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 166. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 167. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 168. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 169. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 170. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 171. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 173. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 174. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 175. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 176. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 177. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 178. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 179. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 180. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 182. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 183. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 184. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 185. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 186. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 187. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 188. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 189. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 191. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 192. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 193. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 194. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 195. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 196. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 197. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 198. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 200. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 201. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 202. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 203. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 204. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 205. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 206. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 207. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 210. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 211. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 212. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 223. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 224. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 225. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 226. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 228. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 229. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 230. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 231. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 232. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 233. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 234. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 235. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 237. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 238. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 239. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 240. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 241. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 242. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 243. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 244. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 246. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 247. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 248. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 249. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 250. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 251. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 252. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 253. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 255. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 256. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 257. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 258. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 259. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 260. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 261. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 262. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 264. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 265. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 266. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 267. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 274. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 275. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 276. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 277. ITALY ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 278. ITALY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 279. ITALY ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 280. ITALY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 282. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 283. ITALY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 284. ITALY ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 285. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 292. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 293. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 294. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 295. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 296. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 297. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 298. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 300. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 301. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 302. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 303. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 304. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 305. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 306. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 307. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 308. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 309. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 310. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 311. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 312. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 313. POLAND ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 314. POLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 315. POLAND ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 316. POLAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 317. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 318. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 319. POLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 320. POLAND ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 321. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 322. QATAR ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 323. QATAR ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 324. QATAR ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 325. QATAR ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 326. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 327. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 328. QATAR ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 329. QATAR ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 330. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 331. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 332. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 333. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 334. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 335. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 336. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS), 2018-2030 (USD MILLION)
TABLE 337. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 338. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY SYNTHETIC DMARDS, 2018-2030 (USD MILLION)
TABLE 339. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 340. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 341. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 342. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY NON-BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 343. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 344. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 345. SAUDI ARABIA ANTI-RHEUMATICS

Companies Mentioned

The leading players in the Anti-Rheumatics Market, which are profiled in this report, include:

AbbVie Inc.
Amgen Inc.
AstraZeneca plc
Biogen Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
Galapagos NV
Gilead Sciences, Inc.
GlaxoSmithKline plc
ILTOO Pharma
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
Roche Holding AG
Sanofi S.A.
UCB S.A.
Vertex Pharmaceuticals Incorporated

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	199
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 63.28 Billion
Forecasted Market Value ( USD ) by 2030	$ 86.09 Billion
Compound Annual Growth Rate	5.1%
Regions Covered	Global
No. of Companies Mentioned	21

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3522EUR$3,545USD£2,928GBP €3913EUR$3,939USD£3,254GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6231EUR$6,272USD£5,181GBP €6923EUR$6,969USD£5,757GBP

Understanding Market Dynamics in the Anti-Rheumatics Market

Exploring Porter’s Five Forces for the Anti-Rheumatics Market

Applying PESTLE Analysis to the Anti-Rheumatics Market

Analyzing Market Share in the Anti-Rheumatics Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Anti-Rheumatics Market

Strategic Recommendations for Success in the Anti-Rheumatics Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Anti-rheumatics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 - (By Drug Class Coverage, Type Coverage, Geographic Coverage and By Company)

Anti-Rheumatics Market Report by Type, Route of Drug Administration, Distribution Channel, and Region 2024-2032

Cell & Gene Therapies in Rheumatology: Therapeutic Analysis

Rheumatology Therapeutics Market by Indication, Distribution Channel - Global Forecast 2025-2030

Rheumatology Therapeutic Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

About the Market